Recombinant DNA: The First Report

Credit: COURTESY OF TERRY SHARRER" /> Credit: COURTESY OF TERRY SHARRER In a series of experiments in the late 1960s and early 1970s, Stanley Cohen, Herbert Boyer, and their colleagues developed the techniques necessary to recombine genes in bacterial plasmids, allowing for their mass production and launching recombinant biotechnology as we know it. In 1973, the Cohen-Boyer team introduced a plasmid fragment from one strain of Escherichia coli, conferring kanamycin resistance in

Written byTerry Sharrer
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In a series of experiments in the late 1960s and early 1970s, Stanley Cohen, Herbert Boyer, and their colleagues developed the techniques necessary to recombine genes in bacterial plasmids, allowing for their mass production and launching recombinant biotechnology as we know it.

In 1973, the Cohen-Boyer team introduced a plasmid fragment from one strain of Escherichia coli, conferring kanamycin resistance into another E. coli plasmid for tetracycline resistance, and then inserted the recombined DNA into live E. coli cells, which showed both characteristics.1 In 1974, they crossed species barriers, joining DNA fragments from Staphylococcus aureus, for ampicillin resistance, with the tetracycline resistance plasmid, and then cloned it into E. coli.2 Next they crossed kingdom barriers, inserting eukaryotic DNA - it was a ribosome gene from the African clawed frog, Xenopus laevis - into E. coli.3

The bacteria not only mass-produced these "molecular chimeras," but they also transcribed the gene, demonstrating ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies